Verona Pharma

Breathtaking science

Developing respiratory drugs to improve health and quality of life

Ligand Pharmaceuticals
Analyst Day, New York
12 March 2019

Nasdaq VRNA
www.veronapharma.com

Forward-Looking Statements

Verona Pharma

This presentation contains "forward-looking" statements that are based on the beliefs and assumptions and on information currently available to management of Verona Pharma plc (together with its consolidated subsidiaries, the "Company"). All statements other than statements of historical fact contained in this presentation are forward-looking statements. Forward-looking statements include information concerning the initiation, timing, progress and results of clinical trials of the Company's product candidate, the timing or likelihood of regulatory filings and approvals for of its product candidate, and estimates regarding the Company's expenses, future revenues and future capital requirements. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other comparable terminology.

Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks, uncertainties and other factors include those under "Risk Factors" in the Company's annual report on Form 20-F filed with the Securities and Exchange Commission (the "SEC") on February 27, 2018, and in its other reports filed with the SEC. Forward-looking statements represent the Company's beliefs and assumptions only as of the date of this presentation. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, the Company assumes no obligation to publicly update any forward-looking statements for any reason after the date of this presentation, or to conform any of the forward-looking statements to actual results or to changes in its expectations.

This presentation also contains estimates, projections and other information concerning the Company's business and the markets for the Company's product candidate, including data regarding the estimated size of those markets, and the incidence and prevalence of certain medical conditions. Information that is based on estimates, forecasts, projections, market research, or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances reflected in this information. Unless otherwise expressly stated, the Company obtained this industry, business, market and other data from reports, research surveys, clinical trials studies and similar data prepared by market research firms and other third parties, from industry, medical and general publications, and from government data and similar sources.

Verona Pharma

Advancing first-in-class product candidate for treatment of respiratory disease from Phase 2 to commercialization

Initial Disease Focus

Chronic Obstructive Pulmonary Disease (COPD)

Novel Drug Candidate
Ensifentrine (RPL554)



Inhaled Inhibitor of Enzymes PDE3 and PDE4

Bronchodilator AND Anti-inflammatory Agent

… in a Single Compound

Demonstrated dual effects and was well tolerated in 13 clinical trials with >800 subjects

Long patent runway until mid-2030s

COPD: The Silent Epidemic

Verona Pharma

Living with It

24M in US alone



16M
Diagnosed

2M
Severe/
very severe

Dying from It



In the Workplace

- **70%** of COPD sufferers work
- **2nd leading cause** of disability

Cost

$50B/year

Indirect & Direct

3rd Largest Chronic Disease Killer

Deaths/Day



Sources: COPD Foundation; US only

Ensifentrine First-in-Class Candidate: Bronchodilator and Anti-inflammatory in Single Compound

Verona Pharma

Ensifentrine: Dual PDE3 and PDE4 Enzyme Inhibitor





Airway Smooth Muscle

PDE3, PDE4

Relaxation

↓

Increased bronchodilation

Inflammatory Cells

Neutrophils
PDE4

Epithelial cells
PDE3, **PDE4**

Macrophages
PDE3, **PDE4**

Eosinophils
PDE4

Lymphocytes
PDE3, **PDE4**

Fibroblasts
PDE4

↓

Increased anti-inflammatory effects

Epithelial Cells

PDE3, **PDE4**

CFTR Activation

↓

Increased mucociliary clearance

Improved lung function, symptom reduction and improved quality of life

4 Week Phase 2b: Rapidly Improved Lung Function and Progressive Symptom Relief as Single Bronchodilator

Verona Pharma

Lung Function

Peak Change FEV_1 (mL) (p<0.001)*



*Peak Change from Day 1 in Baseline in FEV_1 (mL) on Day 28, Week 4, Primary endpoint was met; ensifentrine only bronchodilator in these patients

Symptom Relief

Total Score E-RS: COPD by Week, p<0.02**



** Placebo corrected
§ Minimal clinically important difference

Bronchodilation and anti-inflammatory effect improved lung function and relieved symptoms - may potentially lead to reduction in COPD exacerbations

Phase 2: Improvement in Both FEV1 and Residual Volume on Day 3 when Inhaled on Top of Two Bronchodilators

Verona Pharma

Lung Function FEV1 (mL)#



Residual Volume (mL)



FEV1 (mL) Change from Baseline on Day 3
Day 3 Peak FEV1, primary endpoint was not statistically significant

28% of patients used triple therapy
(inhaled steroid in addition to the two bronchodilators)

Further improved bronchodilation and reduction in residual volume (air trapping) - may lead to symptom improvement in patients already on dual and triple therapy

Nebulized ensifentrine: Systematic Phase 2 Program Informing Phase 3 design

Focus on well-established regulatory endpoints

Verona Pharma

Establish activity + profile in Ph2 →

Standalone
(Dose Ranging)
400 pts
Bronchodilator + anti-inflammatory
Completed 2018

Add-on to Single Therapy
(2 Ind. P2 Studies)
Bronchodilator
Completed 2017

Add-on to Single Therapy
(Dose Ranging)
Bronchodilator + anti-inflammatory*

Add-on to Double/Triple Therapy
Bronchodilator
Completed Jan 2019

End of Phase 2 Meeting with FDA, target 1Q 2020 ↑

A. Potential Pivotal studies: Design and endpoints based on Ph2 to increase chance of positive outcome

1 x study, 6 mo duration
1 x study 6 mo duration w. 6 mo safety extension
-
None or single bronchodilator background
-
Lung function (FEV1), symptom improvement, explore exacerbations in pooled data

B. Planned positioning study for physicians and payors

Add-on treatment to single and dual bronchodilators in COPD

*Expected to begin in 2Q 2019, results expected in 4Q 2019

Opportunity for Ensifentrine: 40% of US COPD Patients Symptomatic Despite Current Treatment

Verona Pharma



1. Mahler et al., Eur Respir J. 2014. 2. Bateman et al., Eur Respir J. 2013 Dec
3. Mullerova H et al., American Journal of Respiratory and Critical Care Medicine . 4. Vestbo J, et al., The Lancet, Vol 389, p. 1919-1929; May 13, 2017

Substantial, addressable US Commercial Opportunity for Nebulized Ensifentrine

Verona Pharma



	Nebulizer use	Nebulizer use
Est. % of Patients	10%	20%
Est. Total Patients	120,000	160,000
Avg. Annual WAC Price	$12,000	$12,000

280,000 target for nebulized ensifentrine

Positive Interim Phase 2 Data with Ensifentrine Dry Powder Inhaler Formulation in COPD

Data from first of two-part clinical trial

Verona Pharma

Dose-dependent, significant and clinically meaningful bronchodilator response



Inhaler usage for maintenance therapy (US estimates)

- ~80-90% mild to very severe COPD patients ~ 5.5 million
- DPI formulation could dramatically expand the clinical utility and commercial potential

DPI Ensifentrine: Potential to Substantially Expand US Commercial Opportunity

Verona Pharma



	Nebulizer	Inhaler use	Nebulizer	Inhaler use
Est. % of Patients	10%	90%	20%	80%
Est. Total Patients	120,000	1.08M	160,000	0.64M
Avg. Annual WAC Price	$12,000	$4,800	$12,000	$4,800

280,000 target for nebulized ensifentrine

1.72Million target for DPI/MDI ensifentrine

Ensifentrine Lifecycle: Expanding the Pipeline Over Time

Verona Pharma

Supporting Trials

Expanding Pipeline	Expanding Indications	Expanding Delivery	Pre-Clinical	Phase 1	Phase 2	Phase 3
	COPD Maintenance (Home)	Nebulizer				2020 – 2022
	COPD Acute (Hospital)	Nebulizer				
	Cystic Fibrosis	Nebulizer				
	Severe Asthma	Nebulizer				
	COPD Maintenance (Home)	DPI				
	COPD Maintenance (Home)	MDI				



Well Financed with Major Healthcare Investors

Verona Pharma

Financial Overview December 31, 2018

Cash and Cash Equivalents	$82.6M[1]
Operating Expenses Year To Date 3Q18	$32.7M[1]
Market cap	$73.7M[2]

Shareholdings[3]



[1]Exchange rate used (US dollars per pound sterling): December 31, 2018: $1.2763
[2]Current issued 105.3M shares or 13.2m ADSs, share price $5.60 on February 28, 2019
[3]As disclosed to the Company in accordance with AIM Rule 26, or through s80 notices and 13F and 13G filings

2019: Potential for Multiple Value Inflection Points as Ensifentrine Advances Towards Phase 3

Verona Pharma



Verona Pharma

Thank you